These novel treatments, Semaglutide , represent a groundbreaking advancement in treating metabolic dysfunction and possibly related disorders. These drugs are categorized as GLP-1 pathway agonists , indicating they function to emulate the body's GLP-1 peptide, enhancing insulin release and suppressing hunger . Despite Tirzepatide each one works som